C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
2.975
+0.055 (1.88%)
Apr 20, 2026, 12:45 PM EDT - Market open
C4 Therapeutics Employees
C4 Therapeutics had 104 employees as of December 31, 2025. The number of employees decreased by 6 or -5.45% compared to the previous year.
Employees
104
Change (1Y)
-6
Growth (1Y)
-5.45%
Revenue / Employee
$345,644
Profits / Employee
-$1,009,558
Market Cap
290.30M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 104 | -6 | -5.45% |
| Dec 31, 2024 | 110 | -35 | -24.14% |
| Dec 31, 2023 | 145 | -1 | -0.68% |
| Dec 31, 2022 | 146 | 25 | 20.66% |
| Dec 31, 2021 | 121 | 22 | 22.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AC Immune | 122 |
| Alector | 103 |
| SAB Biotherapeutics | 86 |
| Orchestra BioMed Holdings | 86 |
| Compugen | 75 |
| Cybin | 50 |
| Protara Therapeutics | 46 |
| Eledon Pharmaceuticals | 33 |
CCCC News
- 11 days ago - C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion - Reuters
- 11 days ago - C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) - GlobeNewsWire
- 26 days ago - C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma - GlobeNewsWire
- 5 weeks ago - C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - C4 Therapeutics to Participate in Upcoming March Conferences - GlobeNewsWire
- 2 months ago - C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma - GlobeNewsWire
- 2 months ago - C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire